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EDITORIAL 
 
Fungal Diseases: the Last Frontier? 
 
M. J. Day 
Editor-in-Chief, School of Veterinary Sciences, University of Bristol, UK 
 
Fungal organisms are ubiquitous in the environment, with the average human breath 
estimated to contain up to 10 fungal spores (Fröhlich-Nowoisky et al., 2009).  Fungi are 
increasingly recognized as an important part of the mammalian microbiome and dysbiosis of 
the fungal population is associated with a range of diseases (Huffnagle and Noverr, 2013; 
Luan et al., 2015).  A wide variety of these agents can cause infection of crops and other 
plants, and localized or systemic infectious disease in man, insects (e.g. bees) and wild and 
domesticated animal species.  However, in contrast to bacterial, viral or parasitic pathogens, 
we know relatively little of the epidemiology of fungal diseases, the pathogenesis and tissue 
pathology related to fungal infection, and the nature of the immune response to these 
organisms. 
 Fungi are generally regarded as opportunist pathogens – causing infection in 
immunodeficient or immunosuppressed individuals, for example, people with primary 
immunodeficiency or haematological disease or those undergoing chemotherapy for cancer or 
being medically immunosuppressed for transplantation surgery or immune-mediated disease.  
Effective therapies for fungal diseases are few in number and there are recent concerns about 
the development of resistance to some treatments (Pfaller and Diekema, 2004).  For example, 
multiple resistance to the azole drugs amongst human isolates of Aspergillus fumigatus has 
increased in the UK from 16% of isolates in 2009 to 38% in 2011 (Busca et al., 2015).  
Resistance is related to a mutation in the fungal cyp51A gene and the increased incidence 
may relate to more widespread and more longterm use of azole drugs in human medicine 
(Busca et al., 2015) and in crop production (Fisher et al., 2012).  Against this background, the 
prevalence of fungal infections appears to be increasing in the human population with 
emergence of new opportunist fungal pathogens (Pfaller and Diekema, 2004; Nucci and 
Marr, 2005; Richardson and Lass-Flörl, 2008).  This increase may partly reflect the 
availability of new diagnostics (e.g. serological testing and computed tomography), but also 
the increased performance of procedures such as transplantation (Low and Rotstein, 2011) 
and the effects of predisposing diseases such as the acquired immunodeficiency syndrome.  
Similarly, there are increasing examples of emerging fungal infections in wildlife species 
(e.g. ‘white nose disease’ in bats caused by Geomyces destructans; chytridiomycosis of 
amphibians caused by Batrachochytrium dendrobatidis) with the survival of some 39 wildlife 
species threatened by fungal diseases (Fisher et al., 2012).  These changes may reflect human 
interventions to the natural environment (e.g. land clearance, climate change) or 
intercontinental dispersal by international animal trade.   The emergence of new diseases in 
new habitats, the increasing prevalence of fungal infections and antifungal drug resistance all 
set new challenges for science. 
 Over the past few months, the Journal of Comparative Pathology has seen a number 
of submissions relating to fungal diseases (or diseases caused by fungus-like eukaryotes) of 
domestic animals and these have been collected together to create this partly themed issue.  
These include case reports of infection by the oomycote, Pythium insidiosum, in the upper 
respiratory tract of two horses in Brazil (Souto et al., 2016), and co-infection with algae 
characterized as Prototheca zopfii genotype 2 and Pithomyces chartarum in a case of equine 
rhinosinusitis from Germany (Shöniger et al., 2016).  Two papers describe feline Aspergillus 
spp. infections.  The first documents two diabetic cats from Brazil with pulmonary infection 
caused by Aspergillus section Nigri and proposes that the infection may have been secondary 
to immunocompromise related to the diabetes mellitus (Viana Leite Filho et al., 2016).  The 
second manuscript uses immunohistochemistry to describe the mucosal immune response to 
invasive upper respiratory tract infection by either Aspergillus felis or Aspergillus fumigatus 
in six cats from Australia (Whitney et al., 2016).  Finally, a large review of avian diseases 
from the USA documents the occurrence of fungal disease in this population (Nemeth et al., 
2016).  Fungal infections accounted for 33% of all infectious diseases recorded in 528 
Psittaciformes and, where identified, the most common causative agents were Aspergillus 
spp. and Candida spp.  Collectively, these papers provide valuable new information on this 
challenging group of pathogens and some comparative insights with equivalent human 
infections. 
 To complete this thematic issue, we delve into the rich historical archive of the 
Journal of Comparative Pathology and reprint two manuscripts providing early descriptions 
of fungal disease.   The first, by Foulerton, was published in 1898 and provides a fascinating 
discourse on the nature of granulomata and describes fungal granulomata in birds and 
animals.   The paper discusses the nature of multinucleated giant cells within granulomata 
and the contemporary proposal by Metchnikoff that these cells are active participants in 
immune defence, rather than being a stage of cellular degeneracy.  This paper also uses the 
descriptive term ‘kunker’ for the firm, coral-like tissue lesions of fungal disease – and the 
same terminology is used in the reports of equine pythiosis in this issue. 
The second manuscript, from 1908, appears to be an anonymous translation of a paper 
by Neumann, published originally in the Revue Véterinaire (July 1st, 1908, p. 417) in the 
same year.  This provides a review of avian aspergillosis, first described as early as 1815.  
The author notes the greater frequency of fungal infection in the respiratory tract of birds 
compared with mammals and relates this to the avian air sacs providing an environment 
conducive to fungal growth.  The paper concludes with a recommended therapy, ‘vapour of 
tar’ that is created by mixing a tablespoon of ‘vegetable tar’ with half a litre of water, after 
which ‘a piece of red-hot iron is plunged in the mixture and stirred about’.   These early, 
carefully-made descriptions of fungal morphology and tissue pathology are not dissimilar to 
those in the current manuscripts, although more than a century later, we at least have access 
to more effective anti-fungal therapies!  There is, however, still much to learn about fungal 
diseases and these infections have rightly been described as the ‘last frontier’ in infectious 
disease research. 
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